PureTech Health announced that enrollment has been completed in the ELEVATE IPF Phase 2b clinical trial evaluating LYT-100 in patients with idiopathic pulmonary fibrosis, or IPF.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- PureTech gets FDA fast track designation for LYT-200 to treat head/neck cancer
- PureTech Health Debuts Seaport Therapeutics and Reshuffles Leadership
- PureTech Health Announces $100 Million Shareholder Return
- PureTech Health announces proposed capital return of $100M
- PureTech Health Entity Acquired for $14 Billion